IN
INCY.US Incyte Corporation
- Market cap
- USD 24.7B
- P/E
- 61.7x
- P/B
- 4.37x
- ROE
- 2.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is INCY.US undervalued?
Graham numberThe Graham number of Incyte Corporation cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Incyte Corporation fundamental analysis
No fundamental analysis for Incyte Corporation yet.
Incyte Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment…
Full company profileIncyte Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Incyte Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.11B | 1.54B | 1.88B | 2.16B | 2.67B | 2.99B | 3.39B | 3.70B | 4.24B | 5.14B | 6.01B |
| Gross Profit | 1.05B | 1.46B | 1.79B | 2.04B | 2.54B | 2.84B | 3.19B | 3.44B | 3.93B | 4.77B | 5.58B |
| Operating Income | 145M | -243M | 129M | 402M | -264M | 586M | 592M | 655M | 101M | 1.34B | 418M |
| EBITDA | 205M | -253M | 172M | 543M | -178M | 630M | 600M | 919M | 408M | 1.76B | 611M |
| Net Income | 104M | -313M | 109M | 447M | -296M | 949M | 341M | 598M | 32.6M | 1.29B | 139M |
| EPS | 0.54 | -1.53 | 0.51 | 2.05 | -1.36 | 4.27 | 1.52 | 2.65 | 0.15 | 6.41 | 0.68 |
| Balance Sheet | |||||||||||
| Total Assets | 1.64B | 2.30B | 2.65B | 3.43B | 3.56B | 4.93B | 5.84B | 6.78B | 5.44B | 6.96B | 7.29B |
| Total Liabilities | 1.22B | 672M | 720M | 828M | 950M | 1.16B | 1.47B | 1.59B | 2.00B | 1.79B | 1.64B |
| Shareholders' Equity | 419M | 1.63B | 1.93B | 2.60B | 2.61B | 3.77B | 4.37B | 5.19B | 3.45B | 5.17B | 5.64B |
| Cash & Short-term Investments | 809M | 1.17B | 1.44B | 2.12B | 1.80B | 2.35B | 3.24B | 3.66B | 2.16B | 3.58B | 3.85B |
| Total Debt | 651M | 24.0M | 36.1M | 60.2M | 47.5M | 44.8M | 41.5M | 38.3M | 38.0M | 40.4M | 37.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 305M | -93.0M | 336M | 711M | -125M | 749M | 970M | 496M | 335M | 1.41B | 269M |
| Capital Expenditure | 120M | 111M | 73.5M | 78.1M | 187M | 181M | 77.8M | 32.5M | 86.3M | 58.9M | 51.0M |
| Free Cash Flow | 184M | -204M | 263M | 633M | -312M | 568M | 892M | 464M | 249M | 1.35B | 218M |
| Ratios | |||||||||||
| ROE | 24.8% | -19.2% | 5.7% | 17.2% | -11.3% | 25.2% | 7.8% | 11.5% | 0.9% | 24.9% | 2.5% |
| ROA | 6.4% | -13.6% | 4.1% | 13.0% | -8.3% | 19.2% | 5.8% | 8.8% | 0.6% | 18.5% | 1.9% |
| Net Profit Margin | 9.4% | -20.4% | 5.8% | 20.7% | -11.1% | 31.8% | 10.0% | 16.2% | 0.8% | 25.0% | 2.3% |
| Debt to Equity | 1.55x | 0.01x | 0.02x | 0.02x | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Incyte Corporation dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 26.3M | 0.12 | 7.7% |
| 2021 | USD 29.9M | 0.13 | 3.2% |
| 2020 | USD 22.8M | 0.10 | - |
| 2019 | USD 16.8M | 0.08 | 3.7% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Sep 1, 2000.
Who owns Incyte Corporation
- Insiders 2.18%
- Institutions 97.82%
- Public & others 0.00%
- Shares outstanding 204M
- Free float 172M
Top funds holding INCY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Dodge & Cox Stock I | 6.66M | 3.27% | -16.26% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 5.48M | 2.69% | +1.39% | Sep 2026 |
| Vanguard 500 Index Investor | 4.47M | 2.19% | +0.35% | Sep 2026 |
| Vanguard Small Cap Index | 3.88M | 1.90% | -0.75% | Sep 2026 |
| Vanguard Health Care Inv | 2.39M | 1.17% | -6.37% | Sep 2026 |
| iShares Core S&P 500 ETF | 2.27M | 1.11% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 2.21M | 1.09% | +1.58% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 2.16M | 1.06% | -3.76% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 2.08M | 1.02% | -0.25% | Oct 2026 |
| Invesco S&P 500® Equal Weight ETF | 1.57M | 0.77% | +0.17% | Oct 2026 |
| iShares Biotechnology ETF | 1.56M | 0.77% | -0.36% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.26M | 0.62% | +2.68% | Oct 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 1.25M | 0.61% | +0.88% | Oct 2026 |
| VictoryShares Free Cash Flow ETF | 1.02M | 0.50% | +0.34% | Oct 2026 |
| Dodge & Cox Balanced I | 906K | 0.44% | -19.63% | Sep 2026 |
| Vanguard Institutional Index I | 901K | 0.44% | +0.47% | Sep 2026 |
| iShares MSCI USA Min Vol Factor ETF | 887K | 0.44% | +0.26% | Oct 2026 |
| First Trust NYSE Arca Biotech ETF | 868K | 0.43% | 0.00% | Oct 2026 |
| iShares Russell Mid-Cap ETF | 714K | 0.35% | -0.06% | Oct 2026 |
| Pacer US Cash Cows 100 ETF | 682K | 0.33% | +0.13% | Oct 2026 |
Top institutions holding INCY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Baker Bros Advisors LP | 30.8M | 15.09% | +0.06% | Jun 2026 |
| BlackRock Inc | 18.0M | 8.85% | -4.98% | Jun 2026 |
| Dodge & Cox | 12.0M | 5.87% | -2.41% | Jun 2026 |
| Vanguard Capital Management, LLC | 11.0M | 5.41% | +0.86% | Jun 2026 |
| State Street Corp | 9.72M | 4.77% | +0.84% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 7.79M | 3.82% | +0.41% | Jun 2026 |
| AQR Capital Management LLC | 5.32M | 2.61% | -8.39% | Jun 2026 |
| Geode Capital Management, LLC | 4.75M | 2.33% | +1.01% | Jun 2026 |
| Amvescap Plc. | 4.08M | 2.00% | +5.42% | Jun 2026 |
| LSV Asset Management | 3.88M | 1.90% | -5.88% | Sep 2026 |
| Wellington Management Company LLP | 3.58M | 1.75% | +9.47% | Jun 2026 |
| Renaissance Technologies Corp | 3.33M | 1.63% | -5.27% | Sep 2026 |
| Morgan Stanley - Brokerage Accounts | 2.95M | 1.45% | +3.44% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 2.74M | 1.35% | -3.03% | Jun 2026 |
| Robeco Institutional Asset Management BV | 2.44M | 1.20% | -2.89% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 2.43M | 1.19% | +6.55% | Sep 2026 |
| The Goldman Sachs Group Inc | 2.31M | 1.13% | -1.93% | Jun 2026 |
| Two Sigma Investments LLC | 2.00M | 0.98% | +381.72% | Jun 2026 |
| Acadian Asset Management LLC | 1.77M | 0.87% | +6.30% | Sep 2026 |
| Northern Trust Corp | 1.76M | 0.86% | -4.74% | Jun 2026 |
Incyte Corporation company profile
- Company name
- Incyte Corporation
- Ticker
- INCY.US
- Exchange
- USA Stocks
- Listed since
- Nov 4, 1993
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,844
- Fiscal year end
- December
- Address
- 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
- Phone
- 302 498 6700
- Website
- incyte.com
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. Incyte Corporation has a clinical trial collaboration with Genmab A/S to evaluate petosemtamab. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Incyte Corporation management
10- Mr. William J. MeuryCEO & Director · born 1968
- Dr. Pablo J. Cagnoni M.D., Ph.D.President and Global Head of R&D · born 1963
- Mr. Thomas TrayPrincipal Financial Officer, VP of Finance & Chief Accounting Officer · born 1978
- Dr. Steven H. Stein M.D.Executive VP, Head of Late-stage Development & Chief Medical Officer · born 1967
- Mr. Mohamed Khairie IssaExecutive Vice President & Head of U.S. Commercial · born 1983
- Mr. Suketu P. UpadhyayExecutive VP & CFO · born 1969
- Mr. Michael James MorrisseyExecutive VP & Head of Global Technical Operations · born 1964
- Ms. Alexis SmithVP & Head of Investor Relations
- Mr. Richard A. Hoffman J.D., M.B.A.Executive VP, General Counsel & Secretary · born 1962
- Ms. Pamela M. MurphyVP of Investor Relations & Corporate Communications · born 1951